Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Matthew Krebs, MB, PhD
Advertisement
Articles by Matthew Krebs, MB, PhD
Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.
Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.
Advertisement
Latest Updated Articles
Matthew Krebs, MB, PhD, Talks Rationale for the PALOMA Trial of Subcutaneous Amivantamab in Solid TumorsPublished: April 13th 2022 | Updated:
- Matthew Krebs, MB, PhD Discusses Phase 1 PALOMA Trial Results of Subcutaneous Amivantamab in Solid Tumors
Published: April 29th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
